Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 4,750 shares at $25.20 ($120K) on 2021-01-26, disclosed to the SEC on 2021-01-28.
Open-market sale of $120k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.20 | 4,325 | $109K | 90.8% |
| 2 | $25.94 | 425 | $11K | 9.2% |
| Total | $25.27 avg | 4,750 | $120K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |